Cargando…

PI16 attenuates response to sorafenib and represents a predictive biomarker in hepatocellular carcinoma

Sorafenib has become the only FDA‐approved first‐line therapy for advanced hepatocellular carcinoma (HCC) for more than 10 years, but there is still no validated predictive or prognostic marker. Peptidase inhibitor 16 (PI16) is a functionally unknown gene in cancer research. This study aimed to dete...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Pusen, Jiang, Zhongyi, Liu, Xueni, Yu, Kanru, Wang, Chunguang, Li, Hao, Zhong, Lin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7541153/ https://www.ncbi.nlm.nih.gov/pubmed/32779397 http://dx.doi.org/10.1002/cam4.3331

Ejemplares similares

Identification of Therapeutic Targets and Prognostic Biomarkers Among Chemokine (C-C Motif) Ligands in the Liver Hepatocellular Carcinoma Microenvironment
por: Jiang, Zhongyi, et al.
Publicado: (2021)

Recipient C7 rs9292795 genotype and the risk of hepatocellular carcinoma recurrence after orthotopic liver transplantation in a Han Chinese population
por: Jiang, Zhongyi, et al.
Publicado: (2021)

Phosphorylated ERK is a potential prognostic biomarker for Sorafenib response in hepatocellular carcinoma
por: Liang, Yuelong, et al.
Publicado: (2017)

Immune Tolerance Induction Using Cell-Based Strategies in Liver Transplantation: Clinical Perspectives
por: Wang, Pusen, et al.
Publicado: (2020)

CD93 overexpresses in liver hepatocellular carcinoma and represents a potential immunotherapy target
por: Jiang, Qianwei, et al.
Publicado: (2023)

Phase II trial of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma after disease progression on sorafenib
por: El Dika, Imane, et al.
Publicado: (2020)

Sorafenib for the treatment of advanced hepatocellular carcinoma with extrahepatic metastasis: a prospective multicenter cohort study
por: Nakano, Masahito, et al.
Publicado: (2015)

Regorafenib for Taiwanese patients with unresectable hepatocellular carcinoma after sorafenib failure: Impact of alpha‐fetoprotein levels
por: Hsu, Po‐Yao, et al.
Publicado: (2021)

Prognosis of patients with hepatocellular carcinoma treated with sorafenib: a comparison of five models in a large Canadian database
por: Samawi, Haider H., et al.
Publicado: (2018)

Impact of age on the prognosis after liver transplantation for patients with hepatocellular carcinoma: a single-center experience
por: Wang, Pusen, et al.
Publicado: (2015)

Hepatic pannexin‐1 mediates ST2(+) regulatory T cells promoting resolution of inflammation in lipopolysaccharide‐induced endotoxemia
por: Wang, Pusen, et al.
Publicado: (2022)

Characterization of response to atezolizumab + bevacizumab versus sorafenib for hepatocellular carcinoma: Results from the IMbrave150 trial
por: Salem, Riad, et al.
Publicado: (2021)

Effect of sorafenib starting dose and dose intensity on survival in patients with hepatocellular carcinoma: Results from a Canadian Multicenter Database
por: Alghamdi, Mohammed A., et al.
Publicado: (2020)

Efficacy and safety of sorafenib plus vitamin K treatment for hepatocellular carcinoma: A phase II, randomized study
por: Haruna, Yoshimichi, et al.
Publicado: (2021)

Sestrin 2 confers primary resistance to sorafenib by simultaneously activating AKT and AMPK in hepatocellular carcinoma
por: Dai, Jimin, et al.
Publicado: (2018)

The clinical efficacy and safety of kanglaite adjuvant therapy in the treatment of advanced hepatocellular carcinoma: A PRISMA-compliant meta-analysis
por: Liu, Jingjing, et al.
Publicado: (2019)

Comparative Metabolomic Profiling of Hepatocellular Carcinoma Cells Treated with Sorafenib Monotherapy vs. Sorafenib-Everolimus Combination Therapy
por: Zheng, Jian-feng, et al.
Publicado: (2015)

Improved survival prediction and comparison of prognostic models for patients with hepatocellular carcinoma treated with sorafenib
por: Labeur, Tim A., et al.
Publicado: (2019)

Compound kushen injection relieves tumor-associated macrophage-mediated immunosuppression through TNFR1 and sensitizes hepatocellular carcinoma to sorafenib
por: Yang, Yang, et al.
Publicado: (2020)

Second‐line treatment of hepatocellular carcinoma after sorafenib: Characterizing treatments used over the past 10 years and real‐world eligibility for cabozantinib, regorafenib, and ramucirumab
por: Fung, Andrea S., et al.
Publicado: (2020)

Evaluation of sorafenib treatment and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma: a comparative study using the propensity score matching method
por: Fukubayashi, Kotaro, et al.
Publicado: (2015)

SNGH16 regulates cell autophagy to promote Sorafenib Resistance through suppressing miR‐23b‐3p via sponging EGR1 in hepatocellular carcinoma
por: Jing, Zhao, et al.
Publicado: (2020)

Prognostic factors in patients with recurrent hepatocellular carcinoma treated with salvage liver transplantation: a single-center study
por: Wang, Pusen, et al.
Publicado: (2016)

First‐line sorafenib sequential therapy and liver disease etiology for unresectable hepatocellular carcinoma using inverse probability weighting: A multicenter retrospective study
por: Shimose, Shigeo, et al.
Publicado: (2021)

Sulfiredoxin‐1 is a promising novel prognostic biomarker for hepatocellular carcinoma
por: Rao, Qian‐Wen, et al.
Publicado: (2020)

Ramucirumab for Patients with Advanced Hepatocellular Carcinoma and Elevated Alpha Fetoprotein Following Non–Sorafenib Systemic Therapy: An Expansion Cohort of REACH-2
por: Finn, Richard S, et al.
Publicado: (2022)

Sorafenib combined with hepatectomy in patients with intermediate-stage and advanced hepatocellular carcinoma
por: Zhuang, Lei, et al.
Publicado: (2017)

The effect of chronic viral hepatitis on prognostic value of inflammatory biomarkers in hepatocellular carcinoma
por: Sellers, Cortlandt M., et al.
Publicado: (2021)

Long Noncoding RNA (lncRNA) Small Nucleolar RNA Host Gene 16 (SNHG16) Predicts Poor Prognosis and Sorafenib Resistance in Hepatocellular Carcinoma
por: Guo, Zhenli, et al.
Publicado: (2019)

Sorafenib treatment in children with relapsed and refractory neuroblastoma: an experience of four cases
por: Okada, Keiko, et al.
Publicado: (2016)

Integrated bioinformatics analysis identified MTHFD1L as a potential biomarker and correlated with immune infiltrates in hepatocellular carcinoma
por: Chen, Junhui, et al.
Publicado: (2021)

Sorafenib for advanced hepatocellular carcinoma (HCC): impact of rationing in the United Kingdom
por: Palmer, D H, et al.
Publicado: (2013)

Successful treatment of aortic dissection during sorafenib therapy for hepatocellular carcinoma
por: Tsuchiya, Atsunori, et al.
Publicado: (2018)

Differences Between Sorafenib and Lenvatinib Treatment from Genetic and Clinical Perspectives for Patients with Hepatocellular Carcinoma
por: Wang, Lei, et al.
Publicado: (2022)

Erianin suppresses hepatocellular carcinoma cells through down-regulation of PI3K/AKT, p38 and ERK MAPK signaling pathways
por: Yang, Liang, et al.
Publicado: (2020)

Tolerance and adverse event profile with sorafenib in Indian patients with advanced hepatocellular carcinoma
por: Ostwal, Vikas, et al.
Publicado: (2017)

Pediatric phase I trial of oral sorafenib and topotecan in refractory or recurrent pediatric solid malignancies
por: Reed, Damon R., et al.
Publicado: (2015)

MiR-27a-3p enhances the cisplatin sensitivity in hepatocellular carcinoma cells through inhibiting PI3K/Akt pathway
por: Yang, Ying, et al.
Publicado: (2021)

Sorafenib in Advanced Hepatocellular Carcinoma: A Nationwide Retrospective Study of Efficacy and Tolerability
por: Køstner, Anne Helene, et al.
Publicado: (2013)

Use of Adjuvant Sorafenib in Liver Transplant Recipients with High-Risk Hepatocellular Carcinoma
por: Shetty, Kirti, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_iite3ld8pcgovlag9age28q3io